Valkyries’ Natalie Nakase takes steps to monitor her health after on-court scare - San Francisco Chronicle
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
A required part of this site couldn’t load. This may be due to a browser
extension, network issues, or browser settings. Please check your
This article is an excerpt. To read the full content, visit the original source. San Francisco Chronicle
Related articles

Good health has been more than good luck for the Valkyries - The IX Sports
The last time a Golden State Valkries player missed a game because of injury was back on August 11, when Janelle Salaun sat out with knee soreness. In a WNBA season with a record number of injuries, the Valkryies have been able to maintain their depth, their momentum and their ability to compete for a title by keeping their players on the floor.

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!